Skip to Content

Red Yeast Rice

Scientific Name(s): Monascus purpureus Went.
Common Name(s): Ang-khak, Beni-koji, Cholestin, Hon-Chi, Hongqu, Koji, Monascus, Red fermented rice, Red mold, Red rice koji, Red rice yeast, Red yeast, Red-koji, Rotschimmelreis, Xuezhikang, Zhibituo, Zhitai

Clinical Overview


M. purpureus is a natural source of mevinolin, the active ingredient of the drug lovastatin, therefore, having beneficial effects in the treatment of hyperlipidemia. However, red yeast rice should not be used in place of lovastatin and regular medical care because of potential product safety concerns related to dietary supplements, and lack of patient monitoring. Evidence also exists for its antibacterial and anticancer effects, as well as its activity on glycemic metabolism.


Red yeast rice is available commercially, primarily as a 600 mg capsule. Most manufacturers suggest an oral dosage of 2 capsules twice a day for a total dose of 2,400 mg/day. Commercial over-the-counter products often contain coenzyme Q10 to supplement low levels of this enzyme in patients with statin myopathy. Clinical trials have used dosages of 1,200 to 3,600 mg/day.


Hypersensitivity to any components of red yeast rice. Anaphylactic reactions in certain populations are documented. Because red yeast rice depletes tissue of coenzyme Q10, which may increase the risk of statin-induced myopathy, patients with muscle damage caused by statins should avoid its use.


Avoid use during pregnancy and lactation. One ingredient in red yeast rice is monacolin K, which is also known as mevinolin or lovastatin and has statin-like activity. Statins are potential teratogens based on theoretical considerations and small case studies. CNS and limb defects have been reported in newborns exposed to statins in utero.


There are many possible drug interactions associated with red yeast rice. Consult a health care provider before using any dietary supplement.

Adverse Reactions

Meta-analysis of the efficacy of 3 red yeast rice preparations (Cholestin, Xuezhikang, and Zhibituo) from 93 randomized trials (9,625 patients) documented no serious adverse reactions. The most common adverse reactions included dizziness, decreased appetite, nausea, stomachache, abdominal distension, and diarrhea. A small number of patients experienced increased serum blood urea nitrogen (BUN) and ALT levels. A meta-analysis showed incidence of liver injury, kidney injury, and muscle symptoms with red yeast rice products was not significantly different compared to control.


The nephrotoxic mycotoxin citrinin has been isolated from some strains of M. purpureus and Monascus ruber. No severe toxicities at high doses have been reported. Not recommended for use in patients with liver or kidney disease.


The recorded use of red yeast rice dates back to the Chinese pharmacopoeia, Pen-ts'ao Kang-Mu (AD 1596), published during the Ming Dynasty.1 The red mold species M. purpureus may be cultivated on starch-containing substrates.2 The purported food and medicinal values of the species date back to 800 AD.3 In 1884, Dutch scientists studied the fungus Monascus after discovering its use by villagers in the colonial island of Java. It was classified and named by the French botanist Philippe Van Tieghem.4 Red yeast rice is derived from rice allowed to ferment with the yeast M. purpureus. In 1895, the M. purpureus species was isolated from red koji, named for the purple color of the culture.5, 6

Red yeast rice has been used in Chinese medicine to strengthen the spleen, promote or improve digestion, eliminate dampness and phlegm, promote or improve blood circulation, and remove blood stasis. During the Ming Dynasty, red yeast rice was described as "sweet in flavor and warm in property."7, 8 The genus Monascus has been used for centuries in Asia as a source of pigment for coloring traditional foods. The medicinal properties of red yeast rice are valued throughout Asia, and the species is also used to make rice wine and as a food preservative for maintaining the color and taste of fish and meat.7 Commercial food applications include coloration of sausage, hams, surimi, and tomato ketchup. The pigment has a long history of use as a food ingredient for Asian consumers, but not in Europe or the United States. However, a study documents the registration of numerous patents obtaining the use of Monascus as a food pigment in Japan, the United States, France, and Germany.9 Additionally, it has been used to enhance the flavor of food in Asian countries.10


Red yeast rice forms naturally occurring hydroxymethylglutaryl-CoA reductase (HMG-CoA) inhibitors,11 a family of natural substances known as monacolins. The major ingredient in red yeast rice is monacolin K, which is also known as mevinolin or lovastatin. Monacolin K is found in some commercial red yeast–related products.8 One chemical study using high-performance liquid chromatography with photodiode array detection documented a total of 14 monacolin compounds, including monacolin K, J, L, M, and X with their corresponding hydroxyl acid forms, as well as dehydromonacolin K, dihydromonacolin L, compactin, and 3-hydroxy-3,5-dihydromonacolin L. Starch is the most abundant ingredient, accounting for 73% of the bulk, while crude protein accounts for 15%.8 Trace elements, magnesium and sodium, are the most abundant metal elements. The total monacolin content is usually 0.4% weight/weight rice.8 Red yeast rice also contains sterols, such as beta-sitosterol and campesterol, that may block cholesterol absorption in the intestines. Unsaturated fatty acids (eg, oleic, linoleic, linolenic acids) and B complex vitamins (eg, niacin) have been isolated and may further help reduce cholesterol.1

Monascus produces several secondary metabolites, such as pigments, monacolins, gamma-aminobutyric acid (GABA), and dimerumic acid.7, 8, 9, 11, 12 A total of 8 pigments called azaphilones are produced by Monascus and include yellow (monascin, ankaflavin, yellow II, and xanthomonascin A), orange (monascorubrin and rubropunctatin), and reddish-purple (monascorubramine and rubropunctamine), each of which may have biological activity.5, 9, 13, 14 Commercial utilization of agro−industrial residues for pigment and enzyme production from M. purpureus is documented.9, 15 The natural pigment of Monascus also improves the organoleptic characteristics of various cheeses.16

Monascidin A, another constituent of Monascus, has been characterized as citrinin by qualitative methods, mass spectra, and nuclear magnetic resonance.17 Citrinin is a myotoxin that is especially toxic to liver and kidney tissues, and is suspected of being a renal carcinogen leading to renal tumors.18 Monacolin K and citrinin are both polyketide derivatives. Chemical methods are available to remove citrinin and retain monacolin K in red yeast rice.18

Uses and Pharmacology

Most research focuses on M. purpureus as a natural source of lovastatin, therefore, having beneficial effects in the treatment of hyperlipidemia. Evidence also exists for its antibacterial and anticancer effects, as well as its activity on glycemic metabolism.19

Alzheimer disease

Red mold rice and its metabolites may be beneficial in Alzheimer disease by inhibiting Abeta-induced neurocytotoxicity, Abeta deposition in the brain, and Abeta synthesis pathway as well as by promoting the neuroprotective factor, soluble amyloid precursor protein alpha.52

Antibacterial activity

The activity of Monascus derivatives depends on the hydrophobicity of pigment derivatives and on the amount of pigment absorbed to the cell surface.13

Animal/In vitro data

Antibacterial activity was found against gram-positive and gram-negative species.1, 20, 21 Orange Monascus pigments have been reported to have weak antibacterial activity, while the red pigment has little to no activity.13 Orange pigments had antimicrobial activities against Bacillus subtilis, Escherichia coli, some filamentous fungi, and yeasts.20 Monascidin A inhibited bacteria from the genera Bacillus, Streptococcus, and Pseudomonas. Two yellow pigments had bacteriostatic activity against B. subtilis and inhibitory activity against Staphylococcus aureus.1

Clinical data

No clinical data exists regarding the use of red yeast rice for its antibacterial effects.

Antioxidant effects

In an in vitro study, polysaccharides derived from red mold rice and red mold dioscorea fermented with M. purpureus were found to exert antioxidant activities such as scavenging of radicals, chelating, and inhibiting linoleic acid peroxidation. Additionally, these polysaccharides were found to possess immunomodulatory effects such as enhanced cell proliferation, phagocytosis, and production of cytokines and nitric oxide.53

Bone formation

Statins may reduce the risk of bone fractures, as well as increase bone formation and bone mass. Red yeast rice stimulated bone formation in rats.43


The mechanism of action may involve monacolin K and red yeast pigment fraction inhibiting de novo cholesterogenesis that is required for tumor growth.6 Monacolin K is an effective anticancer agent that blocks the mevalonate biosynthesis pathway, inducing suppression of cancer growth.22

Animal/In vitro data

Red yeast rice inhibited proliferation and stimulated apoptosis, perhaps through caspases4, 9, 11 and poly(ADP-ribose) polymerase cleavage in human colon adenocarcinoma cell lines.6 Proteomic studies found monacolin K to inhibit cell proliferation through multiple protein expressions (a total of 20 proteins), including peroxiredoxins, cytoskeleton proteins, chaperone proteins, and energy-producing enzymes. Monacolin K may also alter the expression of some redox-related enzymes.22, 23 Three active components of Monascus fermented red yeast rice (monacolin K, monascorubrin, and ankaflavin) have documented antiproliferative effects against tumor cells.22 Red mold rice extract was found to induce cell cycle arrest and apoptosis in MCF-7 breast cancer cells.24 Additionally, M. purpureus fermented products were found to be beneficial in the prevention and treatment of oral cancer. Specifically, treatment was associated with a reduction in the number of tumors, mean tumor volume, and tumor burden.5 Red yeast rice was also found to reduce the volume of prostate tumors in mice with a greater effect noted with red yeast compared with lovastatin.25

Oral administration or topical application of monascorubrin pigment inhibited skin cancer development in mice.6, 26, 27

Rubropunctatin, derived from Monascus, was found to inhibit the growth of the human gastric cancer cell line SH-SY5Y, BCG-823, AGS, and MKN45.28

Clinical data

No clinical data exists for the use of red yeast rice in cancer.


The postulated mechanism of action involves the release of acetylcholine from nerve terminals, which in turn stimulates muscarinic receptors in pancreatic cells, increasing insulin release and resulting in lower plasma glucose.29 Additionally, monascin has been found to act as a peroxisome proliferator–activated receptor (PPAR)-gamma agonist to improve insulin sensitivity.10, 30

Animal/In vitro data

Hon-Chi (red yeast rice fermented with Monascus pilous and M. purpureus) decreased plasma glucose in a dose-dependent manner in rats.29 An increase in plasma insulin or C-peptide was also observed, and similar results were documented in streptozotocin-induced diabetic rats.31 Another study found that Hon-Chi improved insulin sensitivity in rats and delayed development of insulin resistance.2 In a study of rats, monascin administration was found to exert PPAR-gamma agonist activity, as well as increase Nrf2 activation.30 Red mold dioscorea was found to improve glycemic control, exert antioxidant and anti-inflammatory effects, and protect beta-cells in the pancreas.32

Clinical data

No clinical data exists for using red yeast rice for its effects on glycemic control.

Hepatic disease

A murine study of alcoholic liver disease found that treatment with Monascus-fermented red mold rice attenuated elevations in liver function tests (ASTs/ALTs) as well as hepatic triglycerides and total cholesterol accumulation. It was also found to exert antioxidant effects and reduce cytokine levels.47

Orange pigment derivatives of Monascus have been found to exert activity against hepatitis C.48


Monacolin K competitively inhibits HMG-CoA reductase, the enzyme that catalyzes HMG-CoA to mevalonate and then to cholesterol, which results in decreased very low density lipoprotein cholesterol (VLDL-C) and plasma triglycerides, as well as LDL-C.

Animal/In vitro data

In the late 1970s, it was discovered that Monascus metabolites inhibited HMG-CoA reductase, the rate-limiting step in cholesterol biosynthesis.33 Zhitai (0.25% HMG-CoA reductase inhibitors) and Xuezhikang (the ethanolic extract containing 1.1% HMG-CoA reductase inhibitors) have both been extensively studied in China and both contain Monascus.34 In 3 separate animal studies, Xuezhikang was effective in reducing serum cholesterol levels, similar to the effect of lovastatin. Xuezhikang was also found to suppress aortic atherosclerotic plaque formation and lipid accumulation in animal livers. The dose of 0.4 and 0.8 g/kg in 1 report reduced serum cholesterol levels by 44% and 59%, respectively.35

Clinical data

The 2013 American College of Cardiology/American Heart Association Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular (ASCVD) risk in adults did not make a recommendation regarding the use of Xuezhikang (extract of red yeast Chinese rice), because only a single ASCVD outcomes trial was documented and was not available in the United States during the timeframe for evidence review.248

A 2012 published review of literature from 2005 to 2010 consisting of clinical trials involving human patients and focusing on dyslipidemia found red yeast rice to reduce total and LDL-C when compared with placebo. Additionally, when red yeast rice was combined with lifestyle changes or other alternative therapies (eg, niacin, fish oil, octacosanol) and compared with statins, there was no difference between regimens containing red yeast rice or statin therapy on total cholesterol and LDL-C levels.42 Similar results in efficacy were demonstrated in a trial that documented a significantly better side effect profile of red yeast rice (1.2 g/day) compared to simvastatin (20 mg/day) in 60 patients with hyperlipidemia and moderate to low cardiovascular risk. The changes in fatigue scores and physical activity levels from baseline were significantly worse with simvastatin over the 4-week study period (P<0.001 each), whereas they remained unchanged from baseline with red yeast rice. The difference between groups was also statistically significant (P<0.01 and P<0.001, respectively).260

Many Chinese studies evaluating Monascus are available. One major, randomized, multicenter trial involved 446 hyperlipidemic patients with total cholesterol levels greater than 230 mg/dL. At the end of an 8-week treatment, total serum cholesterol was reduced by an average of 23%, triglycerides were reduced by 37%, LDL-C was reduced by 29%, and high-density lipoprotein cholesterol (HDL-C) levels were increased by 20%.36 Red yeast rice reduced lipid ratios including LDL-C levels, total cholesterol/HDL-C, LDL-C/HDL-C, and apolipoprotein B/apolipoprotein A-I in hypercholesterolemic patients.37 Similar results were found in a phase 2 multicenter, double-blind, paralle-group, randomized, placebo-controlled trial conducted in the United States and China that enrolled 116 dyslipidemic patients without coronary artery disease in which 1,200 and 2,400 mg/day of Xuezhikang significantly reduced non-HDL-C by approximately 24% and LDL-C by approximately 27% from baseline to treatment week 12 (P < 0.001 each vs baseline and vs placebo). Treatment was well tolerated. No differences in lipid efficacy end points were observed between American and Chinese participants.255 A meta-analysis reviewed the efficacy of 3 red yeast rice preparations (Cholestin, Xuezhikang, and Zhibituo) from 93 randomized trials (9,625 patients). When compared with placebo, red yeast rice treatment reduced serum total cholesterol, triglycerides, and LDL-C levels, and increased HDL-C levels. Although there were no clinical studies at the time that directly compared red yeast rice with any statin, the efficacy of red yeast rice on lipid modification was comparable with that of the prescription drugs pravastatin, simvastatin, lovastatin, atorvastatin, or fluvastatin. When compared with nonstatin drug therapy, red yeast rice was superior to nicotinate and fish oils, but not to fenofibrate and gemfibrozil. No difference was found between Xuezhikang and Zhibituo in lipid profiles.38, 39 Additionally, a double-blind, crossover, randomized clinical trial in 25 moderately hypercholesterolemic (LDL-C 130 to 190 mg/dL) Italian men found that 4 weeks of monacolins treatment, in combination with Mediterranean dietary advice, resulted in a more favorable change in total cholesterol (−12.45%), LDL-C (−21.99%), and non-HDL-C (−14.67%). The red yeast rice extract product contained 10 mg monacolins and 10 mg coenzyme Q10.249

A systematic review and meta-analysis of 20 randomized studies (N = 6,663) published through November 2014 that evaluated the effect on LDL cholesterol of red yeast rice products with a known content of monacolin K, found the effect of red yeast rice 10 mg/day for 2 months to 3.5 years to be no different from pravastatin 40 mg, simvastatin 10 mg, or lovastatin 20 mg therapy (1.02 mmol/L reduction). In the study that compared red yeast rice with gemfibrozil, red yeast rice was beneficial on all lipid parameters; however, gemfibrozil provided a greater improvement in triglycerides. Additionally, it was more effective than placebo. No difference was found in incidence of kidney or liver injury between intervention and control groups; however, methods for evaluating adverse effects across studies was unclear with a high risk of bias.254 A systematic review of all randomized controlled trials published through May 2015 comparing single preparation red yeast rice with simvastatin in participants with primary hyperlipidemia were assessed to determine efficacy and safety. Data on changes in triglycerides, HDL- and LDL-cholesterol, and total cholesterol were pooled and analyzed. A total of 10 trials (N = 905) were eligible for inclusion and all were conducted in China except for 1 in which the location was not specified. Total daily doses of red yeast rice ranged from 1.2 to 3.6 g given for 4 to 12 weeks; simvastatin doses ranged from 10 mg/day to 20 mg/day and 1 study also included pravastatin as a comparator. Risk of bias was unclear for all trials; most had low risk for addressing incomplete outcome data (70%) and high risk of bias for selective reporting (70%). No significant difference was found between red yeast rice and simvastatin for reduction in triglycerides, total cholesterol, or LDL- or HDL-cholesterol. However, 2 trials showed a significant improvement in LDL-cholesterol favoring red yeast rice and HDL-cholesterol favoring simvastatin. No significant difference in adverse events was reported between groups.256

When combined with policosanols, artichoke leaf extracts, garlic, and pine bark extract, red yeast rice was found to be effective in reducing LDL-C when given for 16 weeks to patients with moderate hypercholesterolemia. Total cholesterol and apolipoprotein B100 were reduced after 4 weeks of supplementation and either stabilized or slightly increased by week 16.40 In another randomized, double-blind, placebo-controlled trial, lifestyle changes combined with the use of red yeast rice in participants yielded a larger reduction in LDL-C levels at weeks 12 and 24 as compared with that of participants receiving red yeast rice and usual care. The addition of phytosterol to red yeast rice therapy did not result in any further reductions in lipid parameters. There were no differences at week 52. Additionally, those receiving red yeast rice with lifestyle changes were more likely to achieve an LDL-C goal of less than 100 mg/dL.41

Italian investigators evaluated a combination product containing berberine, red yeast rice, folic acid, and coenzyme Q10 in statin intolerant patients older than 75 years (n = 80) with total cholesterol higher than 200 mg/dl or LDL-C higher than 160 mg/dl in a 12-month, randomized, single-blind study. There were significant reductions in total cholesterol (−20%), and LDL-C (−31%) (P < 0.05 for both results). No significant changes compared with baseline were seen for liver enzymes or creatine kinase (CK) levels.251 Similar results were seen with a commercially available combination product of 1.5% (5.025 mg) red yeast rice that also contained 30 mg coenzyme Q10, 20 mg procyanidins from grape seed, and 100 mg lecithin. Data from 52 participants with a total fasting cholesterol of higher than 200 mg/dL and triglycerides less than 400 mg/dL revealed that 2 capsules taken twice daily for 8 weeks produced a 22% reduction in LDL cholesterol in 20% of the intervention group and a 15% reduction in total cholesterol (P < 0.001); magnitude of effect on LDL was high and ranged from −8% to 40.5%. No significant differences in creatine-kinase elevation or side effects were noted between treatment and placebo, although muscle aches tended to be more prevalent in the intervention group.253 Extending on data published in a 2014 meta-analysis, studies conducted between 2013 and 2016 were evaluated in a meta-analysis to assess safety and efficacy in treating dyslipidemic adults. An additional 13 studies, 11 of which were randomized controlled trials, and 2 meta-analyses were identified that included 1,246 and 7,467 participants, respectively. The majority of trials used tested multi-ingredient formulations with monacolin K being the most common red yeast rice element used. Other ingredients included artichoke leaf, garlic, pine bark, green tea, ubiquinol, astaxanthin, resveratrol, quercetin, Silybum marianum, octasonol, grapeseed, black pepper seed, guggulsterols, and various vitamins. All 13 studies reported significant decreases in LDL cholesterol compared to placebo, other nutraceuticals, or diet and exercise. No significant differences were noted for HDL, and results regarding total cholesterol and triglycerides were equivocal. No changes in liver or renal function were noted in any of the studies and 10 studies noted no changes in creatine kinase. Other side effects were minimal and included mostly GI effects, such as heartburn, nausea, and abdominal pain.259

Another Italian study evaluated red yeast rice extract in pediatric patients (n = 40; 8 to 16 years of age) with familial hypercholesterolemia (n = 24) and familial combined hyperlipidemia. This randomized, placebo-controlled crossover trial used 200 mg of red yeast rice extract (monacolins 3 mg, policosanols 10 mg) or matching placebo daily for 8 weeks, with a 4-week washout period between treatments. Active treatment was performed similarly in the 2 disease groups, with pooled results showing significant reductions in total cholesterol (−18.5%) and LDL-C (−25.1%) (P < 0.001 for both results). No significant changes were seen in HDL-C, apolipoprotein A-1, liver enzymes or CK levels.252

Statin-naïve adults (n=191) in India with newly diagnosed hyperlipidemia and no evidence of cardiovascular disease experienced a significant improvement in lipid parameters, which was evident in both the placebo and treatment groups. All patients were advised about a healthy lifestyle and diet modifications and then assigned to placebo or a proprietary nutritional supplement (PreLipid) that contained red yeast rice (400 mg), grapeseed, niacin, folic acid, and black pepper. In total, 4 of 5 lipid parameters (total cholesterol, LDL, HDL, and non-HDL cholesterol) were improved significantly in the placebo group and all 5 measures were significantly improved in the supplement group with triglycerides being the 5th measure improved. The improvements seen with the red yeast rice formula were significantly better than those seen by diet and lifestyle (placebo) alone. The supplement was well tolerated but resulted in a significant decrease in ALT compared to placebo. The study was an industry-funded 12-week multicenter, double-blind, randomized controlled trial.258


An aqueous extract of M. purpureus prevented and reversed fructose-induced hypertension in rats and did not affect blood pressure levels in normotensive rats fed a regular diet. The effect is believed to be associated with the GABA contents.3 In another study of hypertensive rats, red mold dioscorea 150 mg/kg as a single dose was found to reduce systolic and diastolic blood pressure values 8 hours after administration. This effect was not noted with red mold rice administration. Higher amounts of GABA, yellow pigments, and higher angiotensin I−converting enzyme activity were noted with red mold dioscorea compared with red mold rice.44

Men's health conditions

In a murine study, Monascus cursory extraction was found to suppress baldness in male mice, decrease prostate-specific antigen levels, reduce tumor volume and incidence in testosterone-induced prostate cancer, and decrease dihydrotestosterone, but not testosterone levels. Further studies are warranted to determine the role of Monascus in alopecia, benign prostatic hyperplasia, and prostate cancer.49

Other cardiovascular effects

In a study of rats infused with angiotensin II, those given 200 mg/kg/day of red yeast rice extract 7 days before the infusion and continued for 28 days were found to have reduced atherosclerotic lesions in the intima of the aorta, as well as suppressed angiotensin II expression. The incidence of abdominal aortic aneurysm was reduced with red yeast rice therapy. Additionally, total cholesterol levels were lower with red yeast rice administration.45

In a randomized, double-blind, placebo-controlled study, 4,870 Chinese patients with coronary heart disease having a history of myocardial infarction (MI) were randomized to receive Xuezhikang 0.6 g twice daily or placebo in addition to conventional therapy. After 4 years, nonfatal MI and deaths from coronary heart disease were 5.72% in the Xuezhikang group compared with 10.41% in the control group (45% relative risk reduction). Secondary end points of stroke, tumor, and percutaneous coronary intervention/coronary artery bypass grafting were significantly reduced with treatment compared with placebo (6.92% vs 10.04%, respectively, P = 0.097).46 The effect of a combination of red yeast rice plus ubiquinone on endothelial function and arterial stiffness was investigated in a double-blind, randomized, placebo-controlled trial in pharmacologically untreated hypercholesterolemic adults (n=40). Total and LDL-C levels improved significantly, starting after 2 months of administration, in patients randomized to treatment (10 mg monacolins from Monascus purpureus and 30 mg emulsioned coenzyme Q10) compared to placebo (P<0.05). Significant improvements were also seen in the vascular parameters; endothelial reactivity improved +6% with treatment and changed −0.3% with placebo (P<0.05). Additionally, a significant benefit was observed in arterial stiffness measurements with red yeast rice-coenzyme Q10 (P<0.05). No significant changes were documented between groups in triglycerides, HDL-C, glucose, transaminases, creatine, or creatine phosphokinase.257

Pulmonary disease

Monascus daily supplementation given to rats was found to decrease cigarette smoke–induced lung injuries through reducing oxidative stress and maintaining antioxidant mechanisms.50 Ankaflavin was found to act as an Nrf2 activator in both lung cancer cells and ovalbumin-challenged mice, attenuating airway inflammation and improving lung injury.51


Red yeast rice is available commercially, primarily in 600 mg capsule form. Most manufacturers suggest an oral dosage of 2 capsules twice a day for a total dose of 2,400 mg/day. Commercial OTC products often contain coenzyme Q10 to supplement low levels of this enzyme in patients with statin myopathy.54 Clinical trials have used dosages of 1,200 to 3,600 mg/day for 4 to 12 weeks 55, 56, 256

Pregnancy / Lactation

Avoid use during pregnancy and lactation. The major ingredient in red yeast rice is monacolin K, which is also known as mevinolin or lovastatin and has statin-like activity. Statins have been identified as potential teratogens based on theoretical considerations and in small case studies.57 CNS and limb defects have been reported in newborns exposed to statins in utero.58


The clinical importance of these interactions has not been determined for consumption of red yeast rice, but caution is warranted.

Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Consider therapy modification.59, 60, 61, 62, 63, 64, 65

Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Monitor therapy.66, 67, 68, 69

Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin. Consider therapy modification.70, 71, 72, 73, 74, 75, 76, 77, 78

Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors. Monitor therapy.79, 80

Calcium Channel Blockers (Nondihydropyridine): May increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin (and possibly other related compounds) may be increased. Monitor therapy.81, 82, 83, 84, 85

Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors. Consider therapy modification.86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased. Avoid combination.99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109

Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Consider therapy modification.110, 111

Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Consider therapy modification.109, 112, 113, 114

DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased. Consider therapy modification.115, 116, 117, 118, 119, 120

Dronedarone: May increase the serum concentration of Red Yeast Rice. In particular, concentrations of the lovastatin-like components may be increased. Monitor therapy.121, 122

Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Monitor therapy.123

Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Monitor therapy.74, 124, 125, 126, 127, 128, 129, 130

Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Monitor therapy.74, 124, 125, 126, 127, 128, 129, 130, 131

Fluconazole: May increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased. Monitor therapy.104, 105, 106, 107, 108, 132, 133, 134, 135, 136

Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Consider therapy modification.137, 138

Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Avoid combination.139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156

Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Consider therapy modification.113, 114, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171

HMG-CoA Reductase Inhibitors: Red Yeast Rice may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Avoid combination.75, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182

Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum. Consider therapy modification.67, 68, 183

Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Consider therapy modification.99, 130, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202

Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Consider therapy modification.203, 204, 205, 206, 207, 208, 209

Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Monitor therapy.204, 206, 207, 208, 209, 210

Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased. Monitor therapy.211

Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Consider therapy modification.137, 138

Proton Pump Inhibitors: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Monitor therapy.188, 191, 212, 213, 214, 215, 216, 217, 218, 219

Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Consider therapy modification.138, 220, 221

Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Consider therapy modification.113, 222

St. John's wort: May increase the metabolism of HMG-CoA Reductase Inhibitors. Monitor therapy.223

Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin. Monitor therapy.224, 225, 226, 227, 228

Vitamin K Antagonists: HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. Monitor therapy.229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242

Adverse Reactions

Use of red yeast rice should be avoided with hypersensitivity to any of its components. Anaphylactic reactions have been reported.243, 244 Because red yeast rice decreases tissue levels of coenzyme Q10, which may increase the risk of statin-induced myopathy, patients with muscle damage caused by statins should avoid its use.54, 245

Meta-analysis of the efficacy of 3 red yeast rice preparations (Cholestin, Xuezhikang, and Zhibituo) from 93 randomized trials (9,625 patients) documented no serious adverse reactions. The most common adverse reactions included dizziness, decreased appetite, nausea, stomachache, abdominal distension, and diarrhea. A small number of patients experienced increased serum BUN and ALT levels.39

A meta-analysis showed incidence of liver injury, kidney injury, and muscle symptoms with red yeast rice products was not significantly different compared to control; however methods for evaluating adverse effects across studies was unclear with a high risk of bias.254

A case report describes a possible association between red yeast rice and peripheral neuropathy. A 60-year-old man developed peripheral neuropathy while receiving imatinib for a metastatic GI tumor, in addition to red yeast rice supplement. Upon discontinuation of red yeast rice, his symptoms abated. He continued imatinib therapy for at least 2 years with no further concerns.246


The nephrotoxic mycotoxin, citrinin, has been isolated from some strains of M. purpureus and M. ruber.12, 246

Studies on Monascus have shown no toxicity at doses much greater than typical dosing in both long- and short-term therapy. In rats fed Monascus at 50 times the human dose, no abnormalities in behavior or in blood and urine testing were seen. One percent to 2% of HMG-CoA reductase (ie, statin) users, in general, experience hepatotoxicity and myopathy.34 Monascus is not recommended for use in patients with liver or kidney disease.247


1. Hsieh PS, Tai YH. Aqueous extract of Monascus purpureus M9011 prevents and reverses fructose-induced hypertension in rats. J Agric Food Chem. 2003;51(14):3945-3950.12822928
2. Erdoğrul O, Azirak S. Review of the studies on the red yeast rice (Monascus purpureus). Turk Electron J Biotechnol. 2004;2(5):37-49.15051242
3. Li Z, Seeram NP, Lee R, et al. Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers. J Altern Complement Med. 2005;11(6):1031-1038.
4. Hsu WH, Pan TM. Monascus purpureus-fermented products and oral cancer: a review. Appl Microbiol Biotechnol. 2012;93(5):1831-1842.22290648
5. Su CF, Liu IM, Cheng JT. Improvement of insulin resistance by Hon-Chi in fructose-rich chow-fed rats. Food Chemistry. 2007;104(1):45-52.10561811
6. Hong MY, Seeram NP, Zhang Y, Heber D. Anticancer effects of Chinese red yeast rice beyond monacolin K alone in colon cancer cells. J Nutr Biochem. 2008;19(7):448-458.17869085
7. Huang Z, Xu Y, Li L, Li Y. Two new Monascus metabolites with strong blue fluorescence isolated from red yeast rice. J Agric Food Chem. 2008;56(1):112-118.18072738
8. Ma J, Li Y, Ye Q, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem. 2000;48(11):5220-5225.11087463
9. Silveira ST, Daroit DJ, Brandelli A. Pigment production by Monascus purpureus in grape waste using factorial design. LWT-Food Sci Technol. 2008;41(1):170-174.
10. Shi YC, Pan TM. Red mold, diabetes, and oxidative stress: a review. Appl Microbiol Biotechnol. 2012;94(94):47-55.22382167
11. Li YG, Liu H, Wang ZT. A validated stability-indicating HPLC with photodiode array detector (PDA) method for the stress tests of Monascus purpureus-fermented rice, red yeast rice. J Pharm Biomed Anal. 2005;39(1-2):82-90.15876509
12. Knecht A, Cramer B, Humpf HU. New Monascus metabolites: structure elucidation and toxicological properties studied with immortalized human kidney epithelial cells. Mol Nutr Food Res. 2006;50(3):314-321.16523442
13. Kim C, Jung H, Kim JH, Shin CS. Effect of Monascus pigment derivatives on the electrophoretic mobility of bacteria, and the cell adsorption and antibacterial activities of pigments. Colloids Surf B Biointerfaces. 2006;47(2):153-159.16423514
14. Hamano PS, Orozco SF, Kilikian BV. Concentration determination of extracellular and intracellular red pigments produced by Monascus sp. Braz Arch Biol Technol. 2005;48:43-49.
15. Daroit DJ, Silveira ST, Hertz PF, Brandelli A. Production of extracellular β-glucosidase by Monascus purpureus on different growth substrates. Process Biochem. 2007;42(5):904-908.
16. Baranová M, Mal'a P, Burdova O, Hadbavný M, Sabolová G. Effect of natural pigment of Monascus Purpureus on the organoleptic characters of processed cheeses. Bull Vet Inst Pulawy. 2004;48:59-62.
17. Blanc PJ, Laussac JP, Le Bars J, et al. Characterization of monascidin A from Monascus as citrinin. Int J Food Microbiol. 1995;27(2-3):201-213.8579990
18. Lee CL, Chen WP, Wang JJ, Pan TM. A simple and rapid approach for removing citrinin while retaining monacolin K in red mold rice. J Agric Food Chem. 2007;55(26):11101-11108.18047280
19. Bianchi A. Extracts of Monascusus purpureus beyond statins-profile of efficacy and safety of the use of extracts of Monascus purpureus. Chin J Integr Med. 2005;11(4):309-313.16417786
20. Kim C, Jung H, Kim YO, Shin CS. Antimicrobial activities of amino acid derivatives of Monascus pigments. FEMS Microbiol Lett. 2006;264(1):117-124.17020557
21. Wong HC, Bau YS. Pigmentation and antibacterial activity of fast neutron- and X-ray-induced strains of Monascus purpureus Went. Plant Physiol. 1977;60(4):578-581.
22. Lin WY, Hsu WY, Hish CH, Pan TM. Proteome changes in Caco-2 cells treated with Monascus-fermented red mold rice extract. J Agric Food Chem. 2007;55(22):8987-8994.17927198
23. Lin WY, Song CY, Pan TM. Proteomic analysis of Caco-2 cells treated with monacolin K. J Agric Food Chem. 2006;54(17):6192-6200.16910707
24. Lee CI, Lee CL, Hwang JF, Lee YH, Wang JJ. Monascus-fermented red mold rice exhibits cytotoxic effect and induces apoptosis on human breast cancer cells. Appl Microbiol Biotechnol. 2013;97(3):1269-1278.22814414
25. Hong MY, Henning S, Moro A, Seeram NP, Zhang Y, Heber D. Chinese red yeast rice inhibition of prostate tumor growth in SCID mice. Cancer Prev Res (Phila). 2011;4(4):608-615.21278313
26. Yasukawa K, Takahashi M, Yamanouchi S, Takido M. Inhibitory effect of oral administration of Monascus pigment on tumor promotion in two-stage carcinogenesis in mouse skin. Oncology. 1996;53(3):247-249.8643229
27. Yasukawa K, Takahashi M, Natori S, et al. Azaphilones inhibit tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mice. Oncology. 1994;51(1):108-112.8265094
28. Zheng Y, Xin Y, S hi X, Guo Y. Cytotoxicity of Monascus pigments and their derivatives to human cancer cells. J Agric Food Chem. 2010;58(17):9523-9528.20707312
29. Chen CC, Liu IM. Release of acetylcholine by Hon-Chi to raise insulin secretion in Wistar rats. Neurosci Lett. 2006;404(1-2):117-121.16762503
30. Hsu WH, Lee BH, Chang YY, Hsu YW, Pan TM. A novel natural Nrf2 activator with PPAR-γ agonist (monascin) attenuates the toxicity of methylglyoxal and hyperglycemia. Toxicol Appl Pharmacol. 2013;272(3):842-851.1756824510.1016/j.taap.2013.07.004
31. Chang JC, Wu MC, Liu IM, Cheng JT. Plasma glucose-lowering action of Hon-Chi in streptozotocin-induced diabetic rats. Horm Metab Res. 2006;38(2):76-81.16523406
32. Shi YC, Liao, JW, Pan TM. Antihypertriglyceridemia and anti-inflammatory activities of Monascus-fermented dioscorea in streptozotocin-induced diabetic rats. Exp Diabetes Res. 2011.2171667910.1155/2011/710635
33. Endo A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot. 1979;32(8):852-854.500505
34. Gurr J, Chang M. Scientific product review (of Cholestin). Pharmanex. 1997;(11):1-6.9296372
35. Zhu Y, et al. Effects of Xuezhizang on blood lipids and lipoprotein concentrations of rabbits and quails with hyperlipidemia. Chin J Pharmacol. 1995;30(1):4-8.
36. Wang, et al. Chin J Exp Ther Prepar Chin Med. 1995;1:1-5.
37. Huang CF, Li TC, Lin CC, Liu CS, Shih HC, Lai MM. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil. 2007;14(3):438-440.17568245
38. Cicero AF, Brancaleoni M, Laghi L, Donati F, Mino M. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med. 2005;13(4):273-278.16338198
39. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;1:4.
40. Barrat E, Zair Y, Ogier N, et al. A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hyperchlosterolemia: a randomized placebo-controlled trial. Int J Food Sci Nutr. 2013;64(7):882-889.23815518
41. Becker DJ, French B, Morris PB, Silvent E, Gordon RY. Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial. Am Heart J. 2013;166(1):187-196.23816039
42. Yang CW, Mousa SA. The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders. Complement Ther Med. 2012;20(6):466-474.23131380
43. Gutierrez G, Mundy B, Rossini G, Garrett I, Chen S, Mundy G. Red yeast rice stimulates bone formation in rats. Nutr Res. 2006;26(3):124-129.
44. Wu CL, Lee CL, Pan TM. Red mold dioscorea has a greater antihypertensive effect than traditional red mold rice in spontaneously hypertensive rats. J Agric Food Chem. 2009;57(11):5035-5041.19489628
45. Xie X, Wang Y, Zhang S, et al. Chinese red yeast rice attenuates the development of angiotensin II-induced abdominal aortic aneurysm and atherosclerosis. J Nutr Biochem. 2012;23(6):549-556.21764282
46. Collaborative Group for China Coronary Secondary Prevention Using Xuezhikang. China coronary secondary prevention study (CCSPS). Zhonghua Xin Xue Guan Bing Za Zhi. 2005;33(2):109-115.15924803
47. Cheng PF, Pan TM. Protective effects of Monascus-fermented red mold rice against alcoholic liver disease by attenuating oxidative stress and inflammatory response. J Agric Food Chem. 2011;59:9950-9957.17724362
48. Sun JM, Kim SJ, Kim GW, et al. Inhibition of hepatitis C virus replication by Monascus pigment derivatives that interfere with viral RNA polymerase activity and the mevalonate biosynthesis pathway. J Antimicrob Chemother. 2012;67(1):49-58.22076990
49. Chiu HW, Chen MH, Fang WH, et al. Preventive effects of Monascus on androgen-related diseases: androgenetic alopecia, benign prostatic hyperplasia, and prostate cancer. J Agric Food Chem. 2013;61(8):4379-4386.23651036
50. Li PC, Tsai WH, Chien CT. Dietary Monascus adlay supplements facilitate suppression of cigarette smoke-induced pulmonary endoplasmic reticulum stress, authophagy, apoptosis and emphysema-related PLGF in the rat. Food Chem. 2013;136(2):765-774.23122125
51. Hsu WH, Lee BH, Huang YC, Hsu YW, Pan TM. Ankaflavin, a novel Nrf-2 activator for attenuating allergic airway inflammation. Free Radic Biol Med. 2012;53(9):1643-1651. 22982045
52. Lee CL, Pan TM. Red mold fermented products and Alzheimer’s disease: a review. Appl Microbiol Biotechnol. 2011;91(30):461-469.21687963
53. Tseng KC, Fang TJ, Chiang SS, Liu CF, Wu CL, Pan TM. Immunomodulatory activities and acntioxidant properties of polysaccharides from Monascus-fermented products in vitro. J Sci Food Agric. 2012;92(7):1483-1489.22144071
54. Yang HT, Lin SH, Huang SY, Chou HJ. Acute administration of red yeast rice (Monascus purpureus) depletes tissue coenzyme Q(10) levels in ICR mice. Br J Nutr. 2005;93(1):131-135.15705235
55. Keithley JK, Swanson B, Sha BE, Zeller JM, Kessler HA, Smith KY. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition. 2002;18(2):201-204.11844656
56. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999;69(2):231-236.9989685
57. Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can. 2007;29(11):906-908.17977494
58. Statins: beware during pregnancy. Prescrire Int. 2006;15(81):18-19.
59. Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother. 2004;38(6):978-981.15069169
60. Wratchford P, Ponte CD. High-dose simvastatin and rhabdomyolysis. Am J Health Syst Pharm. 2003;60(7):698-700.12701554
61. Marot A, Morelle J, Chouinard VA, et al. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin Belg. 2011;66(2):134-136.21630612
62. Merz T, Fuller SH. Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone. Am J Health Syst Pharm. 2007;64(17):1818-1821.17724362
63. Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; October 2011.
64. Mevacor (lovastatin) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; February 2011.
65. Altoprev (lovastatin) [prescribing information]. Weston, FL: Andrx Laboratories, Inc; March 2012.
66. Martin PD, Schneck DW, Dane AL, Warwick MJ. The effect of a combination antacid preparation containing aluminum hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Curr Med Res Opin. 2008;24(4):1231-1235.18355422
67. Yang BB, Smithers JA, Abel RS, et al. Effects of Maalox TC on pharmacokinetics and pharmacodynamics of atorvastatin. Pharm Res. 1996;13(Suppl 9):S437.
68. Mück W, Ritter W, Dietrich H, Frey R, Kuhlmann J. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther. 1997;35(6):261-264.9208343
69. Stern RH, Gibson DM, Whitfield LR. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol. 1998;53(6):475-478.9551707
70. Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol. 2009;65(12):1169-1174.19756555
71. Kyrklund C, Backman JT, Kivistö KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 2001;69(5):340-345.11372002
72. Kajosaari LI, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol. 2004;58(4):390-396.15373931
73. Yamazaki M, Li B, Louie SW, et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica. 2005;35(7):737-753.16316932
74. Neuvonen PJ, Niemi M,Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565-581.17178259
75. Lescol (fluvastatin) [prescribing information]. Dorval, Quebec: Novartis Pharmaceuticals Canada Inc; September 2012.
76. Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis. 2000;150(2):429-436.10856536
77. Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med. 2000;247(5):563-569.10809995
78. Product monograph. Bezalip SR (bezafibrate). Milton, Ontario: Tribute Pharma Canada Inc; June 2011.
79. Dingemanse J, Schaarschmidt D, van Giersbergen PL. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmcokinet. 2003;42(3):293-301.12603176
80. Tracleer (bosentan) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 1999.
81. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 1998;64(4):369-377.9797793
82. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46(8):681-696.17655375
83. Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol. 2001;51:461-470.11422004
84. Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000;67:267-274.10741630
85. Masica AL, Azie NE, Brater DC, Hall SD, Jones DR. Intravenous diltiazem and CYP3A-mediated metabolism. Br J Clin Pharmacol. 2000;50:273-276.10971313
86. Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol. 2007;13(5):266-268.17921794
87. Francis L, Bonilla E, Soforo E, et al. Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol. 2008;27(1):129-131.17628739
88. Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004;30(6):799-802.15389652
89. Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol. 2002;25(5):266-268.12410059
90. Tufan A, Dede DS, Cavus S, et al. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother. 2006;40(7-8):1466-1469.16772404
91. Phanish MK, Krishnamurthy S, Bloodworth LL. Colchicine-induced rhabdomyolysis. Am J Med. 2003;114(2):166-167.12586247
92. Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient. Ann Pharmacother. 2005;39(7-8):1368-1369.15956236
93. Torgovnick J, Sethi N, Arsura E. Colchicine and HMG Co-A reductase inhibitors induced myopathy-a case report. Neorotoxicology. 2006;27(6):1126-1127.17049607
94. Alayli G, Cengiz K, Cantürk F, et al. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005;39(7-8):1358-1361.15914514
95. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005;84(6):377-385.16267412
96. Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol. 1997;53(1):111-116.8960070
97. Dvorak Z, Modriansky M, Pichard-Garcia L, et al. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003;64(1):160-169.12815172
98. Takikawa H, Sano N, Akimoto K, et al. Effects of colchicine and phenothiazine on biliary excretion of organic anions in rats. J Gastroenterol Hepatol. 1998;13(4):427-432.9641309
99. Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother. 1997;31(7-8): 859-863.9220046
100. Landesman KA, Stozek M, Freeman NJ. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. Conn Med. 1999;63(8):455-457.10500341
101. Stein CA, Goel S, Ghavamian R. Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy. Invest New Drugs. 2007;25(3):277-278.17216557
102. Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 1998;46(1):49-53.9690949
103. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1996;60(1):54-61.8689812
104. Lachenmeier DW, Monakhova YB, Kuballa T, et al. NMR evaluation of total statin content and HMG-CoA reductase inhibition in red yeast rice (Monascus spp.) food supplements. Chin Med. 2012;7:8.2243962910.1186/1749-8546-7-8
105. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170(19):1722-1727.20975018
106. US Food and Drug Administration. Warning letter to Swanson Health Products, Inc. August 8, 2007. Accessed May 2012. yeast rice&utm_content=6.
107. US Food and Drug Administration. Warning letter to Nature's Way Products, Inc. January 25, 2008. Accessed May 2012. yeast rice&utm_content=7.
108. US Food and Drug Administration. Warning letter to High Performance Formulas, L.L.C. March 22, 2012. Accessed March 2012.
109. Mevacor (lovastatin) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; February 2012.
110. Ahamed E, Bissett D. Rhabdomyolysis in prostate cancer-caution in prescribing cyproterone acetate with statins. Clin Oncol (R Coll Radiol). 2004;16(8):528-529.15630845
111. Product monograph. Androcur (cyproterone). Toronto, Ontario: Bayer Inc; February 2011.
112. Dallaire M, Chamberland M. Severe rhabdomyolysis in a patient receiving lovastatin, danazol, and doxycycline [article in French]. CMAJ. 1994;150(12):1991-1994.8199978
113. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001;35(9):1096-1107.11573861
114. Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; June 2011.
115. Cubicin (daptomycin) [prescribing information]. Lexington, MA: Cubist Pharmaceuticals, Inc; October 2007.
116. Echevarria K, Datta P, Cadena J, Lewis JS 2nd. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother. 2005;55(4):599-600.15743894
117. Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother. 2006;57(3):578-579.16410267
118. Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis. 2006;42(12):e108-e110.16705566
119. Patel SJ, Samo TC, Suki WN. Early-onset rhabdomyolysis related to daptomycin use. Int J Antimicrob Agents. 2007;30(5):472-474.17804204
120. Veligandla SR, Louie KR, Malesker MA, Smith PW. Muscle pain associated with daptomycin. Ann Pharmacother. 2004;38(11):1860-1862.15367725
121. Multaq (dronedarone) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; June 2009.
122. Mevacor (lovastatin) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; June 2008.
123. Intelence (etravirine) [prescribing information]. Raritan, NJ: Tibotec Therapeutics; January 2008.
124. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol. 2004;94(7):935-938.15464682
125. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95(1):120-122.15619408
126. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(6A):3C-18C.17368275
127. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol. 2004;44(9):1054-1062.15317833
128. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30(11):1280-1287.12386136
129. Goosen TC, Bauman JN, Davis JA, et al. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007;35(8):1315-1324.17470524
130. Livalo (pitavastatin) [prescribing information]. Montgomery, AL: Kowa Pharmaceuticals America, Inc; August 2009.
131. TriLipix (fenofibrate) [prescribing information]. North Chicago, IL: Abbott Laboratories; December 2008.
132. Findling O, Meier N, Sellner J, Nedeltchev K, Arnold M. Clinical reasoning: rhabdomyolysis after combined treatment with simvastatin and fluconazole. Neurology. 2008;71(15):e34-e37.18838657
133. Hazin R, Abuzetun JY, Suker M, Porter J. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc. 2008;100(4):444-446.18481486
134. Moro H, Tsukada H, Tanuma A, et al. Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. AIDS Patient Care STDS. 2004;18(12):687-690.15659879
135. Shaukat A, Benekli M, Vladutiu GD, et al. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother. 2003;37(7-8):1032-1035.12841814
136. Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer, Inc; June 2011.
137. Murphy MJ, Dominiczak MH. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J. 1999;75(884):359-360.10435174
138. Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol. 2003;55(1):94-99.12534645
139. Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia. 2008;63(6):656-658.1847727910.1111/j.1365-2044.2007.05434.x
140. Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust. 2003;179(3):172.12885276
141. Kotanko P, Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron. 2002;90(2):234-235.11818715
142. Dromer C, Vedrenne C, Billey T, et al. Rhabdomyolysis due to simvastin. Apropos of a case with review of the literature [article in French] Rev Rhum Mal Osteoartic. 1992;59(4):281-283.1496277
143. Herring R, Caldwell G, Wade S. Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid. BMJ Case Rep. 2009; 2009.2193158310.1136/bcr.03.2009.1722
144. Collidge TA, Razvi S, Nolan C, et al. Severe statin-induced rhabdomyolysis mimicking Guillain-Barré syndrome in four patients with diabetes mellitus treated with fusidic acid. Diabet Med. 2010;27(6):696-700.20546290
145. Kearney S, Carr AS, McConville J, McCarron MO; Northern Ireland Neurology Network. Rhabdomyolysis after co-prescription of statin and fusidic acid. BMJ. 2012;345:e6562.23047962
146. O'Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J. 2008;84(992):325-327.18644925
147. Wenisch C, Krause R, Fladerer P, El Menjawi I, Pohanka E. Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. Am J Med. 2000;109(1):78.10991749
148. Teckchandani S, Robertson S, Almond A, Donaldson K, Isles C. Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin. J R Coll Physicians Edinb. 2010;40(1):33-36.21125037
149. Magee CN, Medani SA, Leavey SF, Conion PJ, Clarkson MR. Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin. Am J Kidney Dis. 2010;56(5):e11-e15.20888103
150. Kahri J, Valkonen M, Bäcklund T, Vuoristo M, Kivistö KT. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur J Clin Pharmacol. 2005;60(12):905-907.15625612
151. Saeed NT, Azam M. Rhabdomyolysis secondary to interaction between atorvastatin and fusidic acid. BMJ Case Rep. 2009; 2009.21918658
152. Gabignon C, Zeller V, Le Guyader N, et al. Rhabdomyolysis following the coprescription of atorvastatin and fusidic acid [article in French]. Rev Med Interne. 2013;34(1):39-41.23102978
153. Reimann G, Barthel B, Rockstroh JK, Spatz D, Brockmeyer NH. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. Int J Clin Pharmacol Ther. 1999;37(11):562-566.10584978
154. Bode KA, Donner MG, Leier I, Keppler D. Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002;64(1):151-158.12106615
155. Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther. 2005;314(2):876-882.15901796
156. Jemnitz K, Veres Z, Tugyi R, Vereczkey L. Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. Toxicol In Vitro. 2010;24(2):605-610.19853032
157. Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther. 1999;66:118-127.10460065
158. Fukazawa I, Uchida N, Uchida E, Yasuhara H. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol. 2004;57(4):448-455.15025743
159. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 2005;60(5):494-497.16236039
160. Lipitor (atorvastatin) [prescribing information]. New York, NY: Pfizer Inc; June 2009.
161. Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatic acid. Clin Pharmacol Ther. 1998;63(4):397-402.9585793
162. Mevacor (lovastatin) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; May 2010.
163. Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther. 1998;64(5):477-483.9834039
164. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol. 2004;58(1):56-60.15206993
165. Butterweck V, Zdrojewski I, Galloway C, Frye R, Derendorf H. Toxicological and pharmacokinetic evaluation of concomitant intake of grapefruit juice and simvastatin in rats after repeated treatment over 28 days. Planta Med. 2009;75(11):1196-1202.19350484
166. Lilja JJ, Kivistö KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther. 2000;68(4): 384-390.11061578
167. Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther. 2005;312(3):1151-1160.15485894
168. Edwards DJ, Bellevue FH 3rd, Woster PM. Identification of 6′ ,7′ -dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos. 1996;24:1287-1290.8971132
169. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos. 1997;25(11):1228-1233.9351897
170. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997;99(10):2545-2553.9153299
171. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy. 2006;26(11):1601-1607.17064205
172. Hedenmalm K, Alvan G, Ohagen P, Dahl ML. Muscle toxicity with statins. Pharmacoepidemiol Drug Saf. 2010;19(3):223-231.20014178
173. Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22(6):441-457.10877038
174. Backes JM, Howard PA, Ruisinger JF, Moriarty PM. Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother. 2009;43(12):2012-2020.19920157
175. Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol. 2008;66(4):572-574.18637891
176. Rhabdomyolysis linked to Chinese red yeast rice. Prescrire Int. 2008;17(94):64.18516816
177. Polsani VR, Jones PH, Ballantyne CM, Nambi V. A case report of myopathy from consumption of red yeast rice. J Clin Lipidol. 2008;2(1):60-62.21291717
178. Smith DJ, Olive KE. Chinese red rice-induced myopathy. South Med J. 2003;96(12):1265-1267.14696880
179. Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74(8):1200-1201.12438974
180. Venero CV, Venero JV, Wortham DC, Thonpson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol. 2010;105(5):664-666.20185013
181. Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010;105(2):198-204.]2010291810.1016/j.amjcard.2009.08.672
182. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med. 2001;7(2):133-139.11327519
183. Fosrenol (lanthanum) [prescribing information]. Wayne, PA: Shire US Inc; April 2011.
184. Lipitor (atorvastatin) [prescribing information]. New York, NY: Pfizer, Inc; 1999.
185. Mück W, Ochmann K, Rohde G, Unger S, Kuhlmann J. Influence of erythromycin pre- and co-treatment on single dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol. 1998;53(6):469-473.9551706
186. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med. 1988;109(8):682-683.3421582
187. Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J. 1998;91(2):202-205.9496876
188. Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol. 2002;42(4):444-449.11936570
189. Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998;64(2):177-182.9728898
190. Bottorff MB, Behrens DH, Gross A, Markel M. Differences in metabolism of lovastatin and pravastatin as assessed by CYP3A inhibition with erythromycin [abstract]. Pharmacotherapy. 1997;17(1):184.10.1002/j.1875-9114.1997.tb03694.x
191. Sipe BE, Jones RJ, Bokhart GH. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann Pharmacother. 2003;37(6):808-811.12773066
192. Kahri AJ, Valkonen MM, Vuoristo MK, Pentikänen PJ. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. Ann Pharmacother. 2004;38(4):719.14966253
193. Ketec [prescribing information]. Laval, Quebec: Aventis Pharma Inc; 2003.
194. Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2003;59(1):51-56.12682802
195. Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2005;78:342-350.16198653
196. Deng JW, Song IS, Shin HJ, et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008;18(5):424-433.18408565
197. Fujino H, Nakai D, Nakagomi R, et al. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung. 2004;54(7):382-388.15344842
198. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311(1):139-146.15159445]
199. Ieiri I, Suwannakul S, Maeda K, et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2007;82(5):541-547.17460607
200. Hirano M, Maeda K, Matsushima S, et al. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005;68(3):800-807.15955871
201. Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003;33(1):27-41.12519692
202. Yamada I, Fujino H, Shimada S, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans. Xenobiotica. 2003;33(7):789-803.12893526
203. Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; March 2010.
204. Lipitor (atorvastatin) [prescribing information]. New York, NY: Pfizer, Inc; November 2007.
205. Crestor (rosuvastatin) [prescribing information]. Mississauga, Ontario: AstraZeneca Canada Inc; October 2010.
206. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 1988;109(7):597-598.3421570
207. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med. 1988;318(1):46-47.3275891
208. Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol. 2007;99:379-381.17261402
209. Rubenfire M; Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) Study. Am J Cardiol. 2004;94(3):306-311.15276093
210. Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; May 2007.
211. Votrient (pazopanib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2012.
212. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94(9):1140-1146.15518608
213. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother. 2001;35(1):26-31.11197581
214. Chen C, Lin J, Smolarek T, Tremaine L. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab Dispos. 2007;35:1725-1729.17640956
215. Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005;33(4):537-546.15616150
216. Hochman JH, Pudvah N, Qiu J, et al. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004;21(9):1686-1691.15497697
217. Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res. 2000;17(2):209-215.10751037
218. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001;364:551-557.11770010
219. Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, Warhurst G. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharm Sci. 2005;26(5):386-393.16153812
220. Kyrklund C, Backman JT, Kivistö KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 2000;68(6):592-597.11180018
221. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005;78(2):154-167.16084850
222. Gutierrez CA. Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis? Am Fam Physician. 2001;63(4):636-637.11237079
223. Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St. John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther. 2001;70(6):518-524.11753267
224. Product monograph. Yondelis (trabectedin). Toronto, Ontario, Candada: Janssen-Ortho Inc; May 2010.
225. Brain EG. Safety and efficacy of ET-743: the French experience. Anticancer Drugs. 2002;(13)(suppl 1):S11-S14.12173489
226. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001;7(2):231-242.11234874
227. Skorupa A, Beldner M, Kraft A, Montero AJ. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther. 2007;6(7):1015-1017.17611408
228. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22(5):890-899.14990645
229. Ahmad S. Lovastatin. Warfarin interaction. Arch Intern Med. 1990;150(11):2407.2241455
230. O'Rangers EA, Ford M, Hershey A. The effect of HMG-CoA reductase inhibitors on the anticoagulant response to warfarin. Pharmacotherapy. 1994;14(3):349.
231. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother. 1996;30(12):1399-1401.8968451
232. Kline SS, Harrell C. Potential warfarin-fluvastatin interaction. Ann Pharmacother. 1997;31(6):790.9184730
233. Lescol (fluvastatin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2003.
234. Hickmott H, Wynne H, Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost. 2003;89(5):949-950.12719797
235. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for large mortality study. Eur Heart J. 1994;15(2):255-269.8005129
236. Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia. Lancet. 1992;340(8825):979-980.1357387
237. Pravachol (pravastatin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2003.
238. Pan HY. Clinical pharmacology of pravastatin: a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol. 1991;40(Suppl 1):S15-S18.1904355
239. Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol. 1999;39(1):86-90. 9987704
240. Crestor (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2004.
241. Stern R, Abel R, Gibson GL, Besserer J. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol. 1997;37(11):1062-1064.9506000
242. Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy. 2004;24(2):285-290.14998226
243. Wigger-Alberti W, Bauer A, Hipler UC, Elsner P. Anaphylaxis due to Monascus purpureus-fermented rice (red yeast rice). Allergy. 1999;54(12):1330-1331.10688441
244. Hipler UC, Wigger-Alberti W, Bauer A, Elsner P. Case report. Monascus purpureus-a new fungus of allergologic relevance. Mycoses. 2002;45(1-2):58-60.11856440
245. Vercelli L, Mongini T, Olivero N, Rodolico C, Musumeci O, Palmucci L. Chinese red rice depletes muscle coenzyme Q10 and maintains muscle damage after discontinuation of statin treatment. J Am Geriatr Soc. 2006;54(4):718-720.16686894
246. Kumari S, Sherriff JM, Spooner D, Beckett R. Peripheral neuropathy induced by red yeast rice in a patient with known small bowel gastrointestinal tumour. BMJ Case Rep. 2013.10.1136/bcr-2013-009060
247. Bennett JW, Klich M. Mycotoxins. Clin Microbiol Rev. 2003;16(3):497-516.12857779
248. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Nov 7 [Epub ahead of print].2423992310.1016/j.jacc.2013.11.002
249. Cicero AF, Derosa G, Parini A, et al. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res. 2013;33(8):622-628.23890351
250. Childress L, Gay A, Zargar A, Ito MK. Review of red yeast rice content and current Food and Drug Administration oversight. J Clin Lipidol. 2013;7(2):117-122.2341543010.1016/j.jacl.2012.09.003
251. Marazzi G, Cacciotti L, Pelliccia F, Iaia L, et al. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther. 2011;28(12):1105-1113.22113535
252. Guardamagna O, Abello F, Baracco V, Stasiowska B, Martino F. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis. 2011;21(6):424-429.20153154
253. Verhoeven V, Hartmann ML, Remmen R, Wens J, Apers S, Van Royen P. Red yeast rice lowers cholesterol in physicians-a double blind, placebo controlled randomized trial. BMC Complement Altern Med. 2013;13:178.23866314
254. Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain – a systematic review and meta-analysis. Atherosclerosis. 2015;240(2):415-423.25897793
255. Moriarty PM, Roth EM, Karns A, et al. Effects of xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. J Clin Lipidol. 2014;8(6):568-575.25499939
256. Ong YC, Aziz Z. Systematic review of red yeast rice compared with simvastatin in dyslipidaemia. J Clin Pharm Ther. 2016;41(2):170-179.26956355
257. Cicero AF, Morbini M, Rosticci M, D’Addato S, Grandi E, Borghi C. Middle-term dietary supplementation with red yeast rice plus coenzyme Q10 improves lipid pattern, endothelial reactivity and arterial stiffness in moderately hypercholesterolemic subjects. Ann Nutr Metab. 2016;68(3):213-219.27055107
258. Kasliwal RR, Bansal M, Gupta R, et al. EESENS dyslipidemia: a placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia. Nutrition. 2016;32(7-8):767-776.27143594
259. Peng D, Fong A, van Pelt A. The effects of red yeast rice supplementation on cholesterol levels in adults. AJN. 2017;117(8):46-54.28749884
260. Xue Y, Tao L, Wu S, et al. Red yeast rice induces less muscle fatigue symptom than simvastatin in dyslipidemic patients: a single center randomized pilot trial. BMC Cardio Dis. 2017;17(1):127.28521773


This information relates to an herbal, vitamin, mineral or other dietary supplement. This product has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs. This information should not be used to decide whether or not to take this product. This information does not endorse this product as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from your health care provider. You should talk with your health care provider for complete information about the risks and benefits of using this product.

This product may adversely interact with certain health and medical conditions, other prescription and over-the-counter drugs, foods, or other dietary supplements. This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about the herbal, vitamins, mineral or any other supplements you are taking before any kind of surgery or medical procedure. With the exception of certain products that are generally recognized as safe in normal quantities, including use of folic acid and prenatal vitamins during pregnancy, this product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.